BIMR Seminar - Dr. Neil Vasdev - PET Neuroimaging in Drug Discovery

BIMR Seminar - Dr. Neil Vasdev - PET Neuroimaging in Drug Discovery

🎙 Dr. Neil Vasdev 👥 267 📅 September 22, 2025 ⏱ 64 min 👁 133 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

PETradiopharmaceuticalsdrug developmenttau proteinAlzheimer's disease

Summary

Dr. Neil Vasdev, Director of the CAMH Brain Health Imaging Centre, presents a seminar on PET neuroimaging in drug discovery. He begins by explaining the principles of PET imaging and the use of cyclotrons to produce short-lived radionuclides like carbon-11 and fluorine-18. He highlights the historical development of radiochemistry, including the seminal work on [18F]FDOPA at McMaster University. Vasdev emphasizes the importance of PET in de-risking drug development by determining optimal dosing, target engagement, and pharmacokinetics. He discusses his lab’s contributions, such as developing a simplified synthesis for the tau PET tracer [18F]AV-1451 (Tauvid), which became the first FDA-approved radiopharmaceutical for imaging Alzheimer’s disease. He also mentions collaborations with pharmaceutical companies like Merck and Eli Lilly. The talk concludes with a vision for expanding radiochemistry methods and establishing a Canada-wide training program.

132 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation offers valuable insights into the practical applications of PET imaging in drug discovery, supported by concrete examples from the speaker’s extensive experience. The argumentation is solid, demonstrating how radiochemistry innovations can overcome challenges and lead to clinically approved tracers. The speaker effectively argues for the need to move beyond traditional one-step labeling methods and embrace multi-step radiosynthesis to expand the scope of PET imaging.

75 words

Title / Content Match

The title accurately reflects the content, focusing on PET neuroimaging applications in drug discovery.

Quality & Reliability

8/10

Presentation by a leading expert in radiochemistry and PET imaging, with extensive experience in developing FDA-approved tracers. The content is based on peer-reviewed research and practical applications, but lacks detailed citations during the talk.

Key Moments

Cited Sources

Concurring Sources

  • FDA approves Tauvid — FDA approval of the tau PET tracer mentioned in the talk

Contribution & Novelties

The talk provides an expert perspective on the current state and future of PET neuroimaging in drug discovery, emphasizing the importance of innovative radiochemistry. It highlights the speaker’s contributions to FDA-approved tracers and the potential for multi-step radiosynthesis to expand the field.

Pour aller plus loin :

74 words

Radar Profile

The radar profile shows high scores across all dimensions, indicating a well-rounded and reliable presentation. The strongest aspects are the quantity and quality of information, while the technical level is slightly lower, reflecting the intended audience.

Reliability 8/10